

# TABLE OF CONTENTS

June 9, 2008

No. 2093

## BUSINESS

1 Pharma Industry Must Be Trusted by Public: Dr Takenaka  
- Pharma Industry Has Become a Key Industry: Mr Morita

2 Mr Shoda to Lead JPMA to Create Innovation-Friendly NHI Pricing System  
- "Price" Interferes with Innovation  
- Enhance Infrastructures for Drug Discovery

3 Combined Sales Exceed ¥6 Tril. Mark for 23 TSE 1st Section Companies

## TOPICS

3 - Mr Kise of ATOL Elected President of Wholesalers' Fair Trade Council

## Business Results

6 - Tsumura: *Kampo* Medicines Show Robust Growth in Sale of 6.8%

- Meiji Seika: Pharma Sales Up 3.3% due to Strong Sales of Meiact

- Yakult Honsha: Elplat Drives Sales Up 20%

- JCR Pharmaceuticals: Growject Props Up Sales, Profits

- Wakamoto: Preservative-free Nipradilol Eye Drop Contributes to Sales

- Nippon Chemiphar: Aiming at Sales of ¥13 Bil. with Generics

- Combined Sales of 4 Top Wholesalers Exceed ¥6 Tril.

- Teijin to Defend Top Market Share for Drugs for Osteoporosis: Mr Nishikawa

9 Marketing Excellence Japan 2008

- Japan Is a Top-Priority Market for AZ: Dr Keohane

- Japan's Share to Return to 11% in 2011: IMS Japan

10 FJPWA Sets Common Goal for Price Agreement Rate at 70% by End Sept.

- Once-yearly NHI Price Revisions Will Become Reality if *Yakkasa* Remain Too Large

10 NPhA Members Exchange Opinions with Major Wholesalers

- It Is Up to Wholesalers to Make Their Offer Prices Truly Reliable

## BUSINESS NEWS IN BRIEF

10 - Santen to Map US Business Development Policy within FY2008

- Takeda, Alnylam Tie Up for RNAi Therapeutics

- Eisai to Market Prescription Bufferin from July

- Japan Bridge Licenses Granisetron Patch from ProStrakan

- Abilify's Sales Up 24% to US\$454 Mil. in 1st Qtr: MBS

- AnGes MG Obtains Use Patent for HGF Gene in Europe

## GENERICS

13 Top 4 Generic Makers' Combined Sales Up 9.4% to ¥138.9 Bil.

13 Sawai: Sales Up 9.7% with Double-digit Fall in Profits

- Decreases in Profits Are Due to Proactive Investment: Mr Sawai

- New Anti-takeover Program Proposed

14 Towa Pharm.: Sales, Profits Fall Short of Mid-Term Plan

- To Stand Out from Competitors with Orodispersible Tablet

## GENERICS NEWS IN BRIEF

14 - Taiyo Yakuin: Sales Up 9% to ¥37.4 Bil.

- Nichi-iko Expands Production Capacity

- Medisa Shinyaku Doubles Its Production Capacity

## REGULATORY

16 Erbitux, Thymoglobulin, Mycobutin Recommended for Approval

- UMN-0501, Forodesine to Be Designated as Orphan Drugs

17 Galderma's Adapalene, INO Therapeutics' Inoflow Recommended for Approval

- Controlled Release Formulation of Prograf also Recommended for Approval

- Additional Indications for 3 Drugs

- Additional Indication Recommended for Botulinum Toxin

- Orphan Drug Designation for Tacrolimus, Infliximab

## SELF-MEDICATION

19 Approval Recommended for OTC Version of Miconazole for Vaginal Candidiasis

- OTC Drugs Application Classification to Be Revised

## MEDICAL DEVICES

19 DVx's Excimer Laser Lead Withdrawal System Recommended for Approval

## R&D

20 Departure of Global Companies from Japan Is Serious Problem: Mr Yagi

## MEDICAL FACILITIES & NURSING CARE

21 Guidelines on HRT to Be Completed in November

21 Sutent Drug of Choice for Progressive RCC

## Commentary

- Change People's Awareness of Narcotics for Medical Use

## MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF

- *Koroshō* to Set Up Strategy for Development of Anti-hepatitis Treatments

- LDP Committees Call For Withdrawal of Plans to Cut Another ¥220 Bil. in Social Security Spending

- Record-high HIV-Positive Blood Sample Rate Reported in 1st Qtr